Federated Hermes, Inc. Forte Biosciences, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	SELL	$0.96 - $28.0 $1,418 - $41,384	-1,478 Reduced 45.2%	1,792 $1,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.75 $26 - $693	-25 Reduced 0.76%	3,270 $3,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $1.55 $404 - $585	378 Added 12.96%	3,295 $4,000
Q1 2022 May 13, 2022	BUY	$1.21 - $2.24 $1,547 - $2,864	1,279 Added 78.08%	2,917 $4,000
Q4 2021 Feb 14, 2022	BUY	$2.02 - $3.36 $3,308 - $5,503	1,638 New	1,638 $4,000
Q3 2020 Nov 12, 2020	SELL	$14.71 - $50.69 $544 - $1,875	-37 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$13.9 - $24.6 $514 - $910	37 New	37 $1,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$977,456
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $114M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.